We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
+9.27%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$423M
AUM Growth
+$4.74M
(+1.1%)
Cap. Flow
-$21.3M
Cap. Flow
% of AUM
-5.03%
Top 10 Holdings %
Top 10 Hldgs %
48.91%
Holding
89
New
6
Increased
19
Reduced
26
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lexeo Therapeutics
LXEO
|
+$2.99M |
| 2 |
IDEAYA Biosciences
IDYA
|
+$1.87M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$1.69M |
| 4 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$1.2M |
| 5 |
Allogene Therapeutics
ALLO
|
+$1.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$7.9M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$4.27M |
| 3 |
Viking Therapeutics
VKTX
|
+$3.73M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$2.69M |
| 5 |
TSVT
2seventy bio
TSVT
|
+$1.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Neurogene
NGNE
$691M
| $326K | 0.08% |
7,775
-3,225
| -29% | -$125K |
|
|
ADAP
77
DELISTED
Adaptimmune Therapeutics
ADAP
| $324K | 0.08% |
341,064
| – | – |
|
78
Alto Neuroscience
ANRO
$1.11B
| $306K | 0.07% |
26,786
-93,214
| -78% | -$1.14M |
|
79
Neuronetics
STIM
$166M
| $238K | 0.06% |
313,717
| – | – |
|
80
Compass Therapeutics
CMPX
$380M
| $215K | 0.05% |
116,882
| – | – |
|
|
NVRO
81
DELISTED
NEVRO CORP.
NVRO
| $212K | 0.05% |
38,000
+10,000
| +36% | +$70K |
|
82
Spero Therapeutics
SPRO
$72.4M
| $168K | 0.04% |
125,000
| – | – |
|
83
Karyopharm Therapeutics
KPTI
$45.3M
| $160K | 0.04% |
12,845
| – | – |
|
84
Oric Pharmaceuticals
ORIC
$1.34B
| – | – |
-36,000
| Closed | -$255K |
|
85
Procept Biorobotics
PRCT
$1.17B
| – | – |
-13,994
| Closed | -$855K |
|
|
TERN
86
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-86,000
| Closed | -$586K |
|
|
SYRS
87
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| – | – |
-135,850
| Closed | -$701K |
|
|
MORF
88
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| – | – |
-231,748
| Closed | -$7.9M |
|
Similar funds
CDMG
SCP
CAAM
HCM
BOA
DBG
SPT
BCM
DAFNA Capital Management's Q3 2024 Portfolio in Review
As of Q3 2024, DAFNA Capital Management held 89 positions worth $423M, up 1.1% from $419M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
DAFNA Capital Management withdrew a net $21.3M in Q3 2024, closing 5 positions and reducing 26 holdings. Its most notable exit was Morphic Holding, Inc. Common Stock, an estimated $7.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier.
Against the trend, DAFNA Capital Management opened a new position in Lexeo Therapeutics worth $2.27M.
- DAFNA Capital Management's largest Q3 2024 buy was Lexeo Therapeutics: 250,583 shares worth $2.27M.
- DAFNA Capital Management added most to IDEAYA Biosciences in Q3 2024, an estimated $1.87M increase.
- DAFNA Capital Management's biggest Q3 2024 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.27M.
- DAFNA Capital Management fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $7.9M.
- DAFNA Capital Management's ten largest holdings make up 49% of its $423M portfolio in Q3 2024.
- DAFNA Capital Management opened 6 new positions and closed 5 in Q3 2024.
- DAFNA Capital Management's portfolio value rose 1.1% quarter-over-quarter to $423M.
Based on DAFNA Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.